Alpha Teknova, Inc. TKNO
We take great care to ensure that the data presented and summarized in this overview for Alpha Teknova, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TKNO
View all-
Balyasny Asset Management LLC Chicago, IL1MShares$7.73 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny737KShares$5.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$4.34 Million0.0% of portfolio
-
Roubaix Capital, LLC416KShares$3.22 Million1.33% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY366KShares$2.83 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct306KShares$2.37 Million0.0% of portfolio
-
Conestoga Capital Advisors, LLC305KShares$2.36 Million0.02% of portfolio
-
Parian Global Management LP Pound Ridge, NY290KShares$2.24 Million3.15% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT251KShares$1.94 Million0.17% of portfolio
-
Bank Of America Corp Charlotte, NC217KShares$1.68 Million0.0% of portfolio
Latest Institutional Activity in TKNO
Top Purchases
Top Sells
About TKNO
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Insider Transactions at TKNO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 12
2024
|
Telegraph Hill Partners Iv, L.P. |
BUY
Open market or private purchase
|
Indirect |
12,096,773
+50.0%
|
$12,096,773
$1.24 P/Share
|
|
Jul 12
2024
|
Stephen Gunstream President and CEO |
BUY
Open market or private purchase
|
Direct |
80,645
+24.88%
|
$80,645
$1.24 P/Share
|
|
Jul 12
2024
|
Matthew Lowell Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,322
+23.9%
|
$40,322
$1.24 P/Share
|
|
Jun 26
2024
|
Martha J Demski Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Jun 26
2024
|
Brett Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+29.34%
|
-
|
|
Jun 26
2024
|
Alexander Vos Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+29.34%
|
-
|
|
Nov 30
2023
|
Ken Gelhaus Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
3,587
+13.53%
|
$3,587
$1.73 P/Share
|
|
Nov 14
2023
|
Lisa Hood Chief People Officer |
SELL
Other acquisition or disposition
|
Direct |
15,000
-44.33%
|
-
|
|
Sep 19
2023
|
Telegraph Hill Partners Iv, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,190,270
+24.04%
|
$1,190,270
$1.85 P/Share
|
|
Sep 19
2023
|
Telegraph Hill Partners Iv, L.P. |
BUY
Open market or private purchase
|
Direct |
6,917,837
+24.04%
|
$6,917,837
$1.85 P/Share
|
|
Sep 19
2023
|
Damon Terrill General Counsel and CCO |
BUY
Open market or private purchase
|
Direct |
27,027
+39.71%
|
$27,027
$1.85 P/Share
|
|
Sep 19
2023
|
Stephen Gunstream President and CEO |
BUY
Open market or private purchase
|
Direct |
54,054
+24.92%
|
$54,054
$1.85 P/Share
|
|
Sep 19
2023
|
Matthew Lowell Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
54,054
+38.04%
|
$54,054
$1.85 P/Share
|
|
Sep 19
2023
|
J Matthew Mackowski Director |
BUY
Open market or private purchase
|
Indirect |
810,810
+50.0%
|
$810,810
$1.85 P/Share
|
|
Aug 31
2023
|
Robert Mc Namara Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,815
-66.79%
|
-
|
|
Jun 13
2023
|
Lisa Hood Chief People Officer |
SELL
Open market or private sale
|
Direct |
11,400
-25.2%
|
$34,200
$3.8 P/Share
|
|
Jun 02
2023
|
Robert Mc Namara Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,815
+40.04%
|
-
|
|
Jun 02
2023
|
Brett Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,815
+40.04%
|
-
|
|
Jun 02
2023
|
Alexander Vos Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,815
+40.04%
|
-
|
|
May 26
2023
|
Irene Davis Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+0.05%
|
$6,000
$3.22 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 12.2M shares |
|---|---|
| Grant, award, or other acquisition | 60K shares |